Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised
Idefirix is a medicine used to prevent the body from rejecting a newly transplanted kidney.
Idefirix is used before transplantation in adults who have antibodies against the donor kidney and are considered ’highly sensitised’ based on a positive crossmatch test. It should be reserved for patients who are unlikely to obtain a transplant under the available kidney allocation system.
Graft organ rejection following solid organ transplantation is rare, and Idefirix was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 January 2017.
Idefirix contains the active substance imlifidase.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
